A Randomized, Double-Blind, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Effect on Pharmacodynamic Biomarkers of an Intravenous Infusion of R1671 in Patients With Mild, Intermittent Asymptomatic Asthma.
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2014
At a glance
- Drugs R 1671 (Primary)
- Indications Asthma
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors Roche
- 17 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jul 2009 Actual patient number (43) added as reported by ClinicalTrials.gov.
- 15 May 2009 Planned end date changed from 1 Aug 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov record.